Table 2.
Therapeutic aspects of lncRNAs in various diseases with oligonucleotide therapeutics.
| LncRNAs | Oligonucleotide therapeutics | Function | Diseases | References |
|---|---|---|---|---|
| LINC02273 | ASOs | Inhibit breast cancer metastasis | Breast cancer | (115) |
| AC104041.1 | ASOs | Induced antitumor activity | Head and neck squamous cell carcinomas | (116) |
| MALAT1 | ASOs | Inhibited tumor growth and metastasis | Breast cancer and Lung cancer | (117, 118) |
| ASMER-1/2 | ASOs | Regulated adipogenesis, lipid mobilization and adiponectin secretion. | Obesity and/or the insulin resistant state. | (119) |
| Small molecule inhibitors | ||||
| GAS5 | NP-C86 | Increased GAS5 levels and glucose uptake in diabetic adipocytes | Diabetic | (120) |
| MIR155HG | NSC141562 | Inhibition of glioma cell proliferation, migration, and invasion | Glioma | (121) |
| HULC | YK-4-279 | Inhibition of Ewing sarcoma cell growth | Ewing sarcomas | (122) |
| HOTAIR | AC1Q3QWB | Blocked PRC2 recruitment and increased tumor suppressors expression | Breast cancer and glioblastoma | (123) |
| CRISPR/Cas systems | ||||
| PVT1 | CRISPR interference | Enhanced breast cancer cell competition and growth | Breast cancer | (124) |
| UCA1 | Knockout | Inhibition of tumorigenesis | Bladder cell carcinoma | (125) |
| LINC01116 | Knockout | Decreased the ability of the prostate cancer cells | Prostate cancer | (126) |
| Lnc-PANDAR | Knockout | Inhibition of malignant features and tumor growth | Gastric cancer | (127) |
| MANTIS | Knockout | Inhibition of endothelial angiogenic function | Idiopathic pulmonary arterial hypertension | (128) |
| Blnc1 | Knockout | Inhibition of hepatic steatosis and insulin resistance | Obesity and NAFLD | (20) |